An international research team, led by Shinghua Ding at the University of Missouri, has identified a previously unknown ...

Researchers showed that large motor neurons face high metabolic stress, making them more prone to degeneration. Reducing this ...

ALS, also known as Lou Gehrig's disease, is among the most challenging neurological disorders: relentlessly progressive, ...

When Lewis Moody revealed this week that he had been diagnosed with motor neurone disease (MND), the reaction was ... It’s a progressive disease that is often separated into subtypes but symptoms ...

A new Motor Neurone Disease research nurse has joined the highly-acclaimed team at Leeds Teaching Hospitals, to help patients take part in vital trials. Her position is funded by the MND Association ...

When Doddie Weir was diagnosed with motor neurone disease (MND) in 2016, little was made of links between the debilitating condition and rugby. The Scotland legend, who made 61 caps for his country ...

Former England rugby union captain Lewis Moody has been diagnosed with motor neurone disease. The 47-year-old was part of the England squad that won the 2003 Rugby World Cup and went on to represent ...

Discussing his diagnosis, he said: 'You're given the this diagnosis of MND and we're rightly quite emotional about it, but it's so strange because I feel like nothing's wrong. 'I'm still capable of ...

Former England rugby captain Lewis Moody has been diagnosed with motor neurone disease (MND). The 47-year-old flanker, who won several titles throughout his 16-year career, discovered he had the ...

(CNN) — Former England rugby captain and World Cup winner Lewis Moody has been diagnosed with motor neuron disease, he announced on Monday. The 47-year-old, who was part of England’s 2003 Rugby World ...

This week, Bobbi Conner talks with Dr. Sarah Breevoort about early diagnosis and treatment for ALS (Lou Gehrig’s disease). Dr. Breevoort is a physiatrist and Director of the ALS Clinic at MUSC. Conner ...

Late-stage biopharma Scholar Rock (SRRK) is approaching a pivotal catalyst: the FDA decision on apitegromab, its investigational muscle-targeted therapy for spinal muscular atrophy (SMA). A verdict is ...